Literature DB >> 3524432

Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy.

D J Phelps, D D Carlton, C A Farrell, R E Kessler.   

Abstract

Strains of Escherichia coli, Enterobacter aerogenes, and Enterobacter cloacae that were resistant to ceftazidime (MIC greater than 16 micrograms/ml) but susceptible to BMY 28142 (MIC less than 4 micrograms/ml) were found to contain higher levels of beta-lactamase activity (50- to 3,340-fold) than control strains of the corresponding species. Ceftazidime was at least as resistant as BMY 28142 to hydrolysis by these enzymes. However, the apparent Ki of BMY 28142 for each enzyme was larger (8- to greater than 20-fold) than that of ceftazidime; i.e., the affinity of these enzymes for BMY 28142 appeared to be lower than that for ceftazidime. Thus, BMY 28142 was affected less than ceftazidime by a mechanism of resistance that depends, at least in part, on the relative affinities of cephalosporins for the beta-lactamases of these species. These results indicate that the affinity between a beta-lactamase and a cephalosporin may be a distinguishing factor in the evaluation of beta-lactamase-resistant cephalosporins and suggest that affinity can play a major role in susceptibility to highly beta-lactamase-resistant cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524432      PMCID: PMC284164          DOI: 10.1128/AAC.29.5.845

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

Review 2.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

3.  Influence of spontaneous and inducible beta-lactamase production on the antimicrobial activity of recently developed beta-lactam compounds.

Authors:  W Cullmann; W Opferkuch; M Stieglitz; W Dick
Journal:  Chemotherapy       Date:  1984       Impact factor: 2.544

4.  Relation between beta-lactamase production and antimicrobial activity: comparison of the new compound HR 810 with cefotaxime.

Authors:  W Cullmann; W Opferkuch; M Stieglitz
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

5.  Beta-lactamase-directed barrier for penicillins of Escherichia coli carrying R plasmids.

Authors:  T Yamamoto; T Yokota
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

6.  Role of beta-lactam hydrolysis in the mechanism of resistance of a beta-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum beta-lactams.

Authors:  H Vu; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

7.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

8.  A model system to demonstrate that beta-lactamase-associated antibiotic trapping could be a potential means of resistance.

Authors:  L Gutmann; R Williamson
Journal:  J Infect Dis       Date:  1983-08       Impact factor: 5.226

9.  Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.

Authors:  R E Kessler; M Bies; R E Buck; D R Chisholm; T A Pursiano; Y H Tsai; M Misiek; K E Price; F Leitner
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

10.  Chromosomal beta-lactamases of Enterobacter cloacae are responsible for resistance to third-generation cephalosporins.

Authors:  A H Seeberg; R M Tolxdorff-Neutzling; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

View more
  31 in total

1.  Effects of age and gender on pharmacokinetics of cefepime.

Authors:  R H Barbhaiya; C A Knupp; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  R H Barbhaiya; C A Knupp; M Pfeffer; D Zaccardelli; G M Dukes; W Mattern; K A Pittman; L J Hak
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

3.  Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.

Authors:  R H Barbhaiya; S T Forgue; C R Gleason; C A Knupp; K A Pittman; D J Weidler; R R Martin
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents.

Authors:  H Nikaido; W Liu; E Y Rosenberg
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

5.  Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains.

Authors:  O Mimoz; A Jacolot; S Leotard; N Hidri; K Samii; P Nordmann; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 6.  Clinical importance of inducible beta-lactamases in gram-negative bacteria.

Authors:  C C Sanders; W E Sanders
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

7.  Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.

Authors:  D Voutsinas; T Mavroudis; A Avlamis; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 8.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

9.  Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome.

Authors:  H Kieft; A I Hoepelman; M Rozenberg-Arska; J M Branger; J H Voskuil; A B Geers; M Kluyver; H C Hart; E Poest-Clement; L van Beugen
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Combination effect of SCE-2787 and cefepime with aminoglycosides on nosocomial gram-negative bacteria.

Authors:  J Hübner; D Hartung; A Kropec; F D Daschner
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.